Article
24-Nor-ursodeoxycholic acid counteracts T <sub>H</sub> 17/Treg imbalance and ameliorates intestinal inflammation by restricting glutaminolysis in differentiating T <sub>H</sub> 17 cells
2022-02-10
Abstract excerpt
<h4>Objective</h4> 24-Nor-ursodeoxycholic acid (NorUDCA) is a novel therapeutic bile acid for treating primary sclerosing cholangitis (PSC), an immune-mediated cholestatic liver disease. Since PSC strongly associates with inflammatory bowel diseases (IBD) driven by T H 17/Treg imbalance, we aimed to explore NorUDCA’s immunomodulatory potential on intestinal T H 17/Treg balance. <h4>Design</h4> NorUDCA’s impac...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7fe45a23-3125-5bd6-8ba2-9c89bd94c512
- DOI
- 10.1101/2022.02.10.479975
